Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy
Pharmaceutics · 18.03.2024 · 16 (3) · 414
DOI: 10.3390/pharmaceutics16030414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 18.03.2024. Verfasst von Lorenzo Monarca und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Biology and Biotechnologies, University of Perugia, Via dell'Elce di Sotto 8, 06123 Perugia, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Universities and Research, Ministero dell’Istruzione, dell’Università e della Ricerca, Italy, European Union–NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem.
Abstract (Originalsprache)
Human glioblastoma is probably the most malignant and aggressive among cerebral tumors, of which it represents approximately 80% of the reported cases, with an overall survival rate that is quite low. Current therapies include surgery, chemotherapy, and radiotherapy, with associated consistent side effects and low efficacy. The hardness in reaching the site of action, and overcoming the blood–brain barrier, is a major limitation of pharmacological treatments. In this paper, we report the synthesis and characterization of ZIF-90 (ZIF, Zeolitic Imidazolate Framework) nanoparticles as putative carriers of anticancer drugs to the brain. In particular, we successfully evaluated the biocompatibility of these nanoparticles, their stability in body fluids, and their ability to uptake in U251 human glioblastoma cell lines. Furthermore, we managed to synthesize ZIF-90 particles loaded with berberine, an alkaloid reported as a possible effective adjuvant in the treatment of glioblastoma. These findings could suggest ZIF-90 as a possible new strategy for brain cancer therapy and to study the physiological processes present in the central nervous system.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Biology and Biotechnologies, University of Perugia, Via dell'Elce di Sotto 8, 06123 Perugia, Italy.
- Department of Experimental Medicine, Perugia Medical School, University of Perugia, 06132 Perugia, Italy.
- Department of Medicine and Surgery, Institute of Hematology, Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, 06129 Perugia, Italy.
ORCID-Profile: Federico Palazzetti, Paolo Sportoletti, Ferdinando Costantino
Förderung
- Ministry of Education, Universities and Research
- Ministero dell’Istruzione, dell’Università e della Ricerca, Italy
- European Union–NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem
- Ministero dell’Istruzione, dell’Università e della Ricerca (MUR), Italy, Fondo Integrativo Speciale per la Ricerca (FISR 2020)
Zitieren
APA
Monarca, L., Ragonese, F., Sabbatini, P., Caglioti, C., Stamegna, M., Palazzetti, F., Sportoletti, P., Costantino, F., & Fioretti, B. (2024). Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy. Pharmaceutics, 16(3), 414. https://doi.org/10.3390/pharmaceutics16030414
Vancouver
Monarca L, Ragonese F, Sabbatini P, Caglioti C, Stamegna M, Palazzetti F, et al. Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy. Pharmaceutics. 2024;16(3):414. doi:10.3390/pharmaceutics16030414
BibTeX
@article{Monarca2024,
author = {Monarca, Lorenzo and Ragonese, Francesco and Sabbatini, Paola and Caglioti, Concetta and Stamegna, Matteo and Palazzetti, Federico and Sportoletti, Paolo and Costantino, Ferdinando and Fioretti, Bernard},
title = {Synthesis and Characterization of ZIF-90 Nanoparticles as Potential Brain Cancer Therapy},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {3},
pages = {414},
doi = {10.3390/pharmaceutics16030414}
}
EUVIMED